Get the Stockscreener App
27.48
1.11%
-0.305
Overview
News
Price History
Option Chain
Financials
Why PFE Down?
Discussions
Forecast
Stock Split
Dividend History
Pfizer Inc stock is traded at $27.48, with a volume of 15.42M.
It is down -1.11% in the last 24 hours and up +1.56% over the past month.
Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion. While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13 and cardiology drugs Vyndaqel and Eliquis. Pfizer sells these products globally, with international sales representing 40% of total sales. Within international sales, emerging markets are a major contributor.
See More
Previous Close:
$27.78
Open:
$27.69
24h Volume:
15.42M
Relative Volume:
0.38
Market Cap:
$156.54B
Revenue:
$63.32B
Net Income/Loss:
$7.52B
P/E Ratio:
21.06
EPS:
1.3043
Net Cash Flow:
$9.48B
1W Performance:
-4.65%
1M Performance:
+1.56%
6M Performance:
+1.15%
1Y Performance:
+11.81%
1-Day Range:
$27.40
$27.75
1-Week Range:
$27.40
$28.69
52-Week Range:
$23.58
$29.21
Pfizer Inc Stock (PFE) Company Profile
Name
Pfizer Inc
Sector
Industry
Phone
(212) 733-2323
Address
66 HUDSON BOULEVARD EAST, NEW YORK, NY
Compare PFE vs LLY, JNJ, ABBV, MRK, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PFE
Pfizer Inc
|
27.46 | 158.34B | 63.32B | 7.52B | 9.48B | 1.3043 |
LLY
Lilly Eli Co
|
1,126.69 | 1.00T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
266.86 | 643.64B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
252.66 | 443.39B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
144.68 | 363.98B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
137.93 | 261.31B | 54.66B | 13.58B | 16.05B | 7.0171 |
Pfizer Inc Stock (PFE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-02-26 | Upgrade | Argus | Hold → Buy |
| Feb-25-26 | Initiated | RBC Capital Mkts | Underperform |
| Feb-20-26 | Initiated | Barclays | Underweight |
| Feb-12-26 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Jan-07-26 | Resumed | UBS | Neutral |
| Dec-02-25 | Resumed | Citigroup | Neutral |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Neutral |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Nov-15-24 | Initiated | Wolfe Research | Underperform |
| Oct-25-24 | Resumed | Citigroup | Neutral |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Aug-07-24 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Mar-22-24 | Downgrade | Argus | Buy → Hold |
| Feb-23-24 | Initiated | Guggenheim | Buy |
| Jan-04-24 | Downgrade | TD Cowen | Outperform → Market Perform |
| Oct-20-23 | Resumed | UBS | Neutral |
| Oct-16-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-17-23 | Reiterated | JP Morgan | Neutral |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Jun-29-23 | Downgrade | Credit Suisse | Outperform → Neutral |
| May-11-23 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Feb-07-23 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Jan-26-23 | Downgrade | UBS | Buy → Neutral |
| Jan-17-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jan-04-23 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-13-22 | Upgrade | Goldman | Neutral → Buy |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| Apr-06-22 | Resumed | Morgan Stanley | Equal-Weight |
| Jan-05-22 | Upgrade | BofA Securities | Neutral → Buy |
| Jan-03-22 | Reiterated | Bernstein | Mkt Perform |
| Dec-20-21 | Reiterated | Cowen | Outperform |
| Dec-17-21 | Initiated | Goldman | Neutral |
| Dec-13-21 | Upgrade | UBS | Neutral → Buy |
| Dec-09-21 | Initiated | Wells Fargo | Overweight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Jul-27-21 | Resumed | Truist | Buy |
| May-06-21 | Downgrade | Mizuho | Buy → Neutral |
| Apr-07-21 | Resumed | RBC Capital Mkts | Sector Perform |
| Feb-04-21 | Upgrade | DZ Bank | Hold → Buy |
| Dec-16-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-19-20 | Resumed | Goldman | Neutral |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Oct-12-20 | Downgrade | Atlantic Equities | Overweight → Neutral |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Jun-16-20 | Initiated | SVB Leerink | Mkt Perform |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Feb-27-20 | Upgrade | Standpoint Research | Hold → Buy |
| Feb-06-20 | Initiated | Mizuho | Buy |
| Jan-07-20 | Initiated | RBC Capital Mkts | Outperform |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Jul-30-19 | Downgrade | BofA/Merrill | Buy → Neutral |
| Jul-30-19 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-04-19 | Resumed | Morgan Stanley | Overweight |
| Feb-20-19 | Resumed | Citigroup | Neutral |
| Jan-31-19 | Upgrade | Argus | Hold → Buy |
| Jan-31-19 | Upgrade | Credit Suisse | Neutral → Outperform |
| Jan-23-19 | Downgrade | UBS | Buy → Neutral |
| Dec-11-18 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-01-18 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
View All
Pfizer Inc Stock (PFE) Latest News
Pfizer Stock: Firing On All Cylinders (NYSE:PFE) - Seeking Alpha
Pfizer Inc. stock steadies as analysts lift targets and 2026 guidance firms - ad-hoc-news.de
Novartis India zooms 51% in 3 days; what's driving the pharma stock? - Business Standard
Pfizer stock heads into the open after a 2.3% slide - ad-hoc-news.de
Jim Cramer Picks J&J (JNJ) Over Eli Lilly (LLY) and Pfizer (PFE) Among These Healthcare Stocks - Yahoo Finance
Pfizer Inc. stock slips as BMO Capital keeps positive stance and options activity spikes - ad-hoc-news.de
Novartis-Pfizer trademark deal has opposite impact on their stock prices; Novartis India jumps 20% while Pfizer slips 3% - BusinessLine
Pfizer Stock Rises Almost 9% in 3 Months: Time to Buy, Hold or Exit? - Yahoo Finance
Novartis India to Acquire Pfizer’s BP Drug Brands for ₹1,250 Crore - Chemical Industry Digest
Mandi Rollerson Takes on New AI Change and Adoption Leadership Role at Pfizer - hrtoday.in
Monoclonal Antibodies Market to Grow at 11.01% CAGR, Reaching USD 791.28 Billion by 2035 – SNS Insider - GlobeNewswire Inc.
Why Pfizer Stock Was so Healthy in August - Yahoo Finance
Inside Pfizer’s Fight Against Counterfeit Medicine - Pfizer
Pfizer Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Why Is Pfizer (NYSE:PFE) Trading At Such A Wide Discount To Its Healthcare Peers? - Kalkine Media
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference - businesswire.com
💊 Pfizer to discontinue Minipress XL in India 🤝 Novartis India buys the brand for ₹1,250 crore 📉 But Pfizer India gets just ₹131 crore of the deal Ekta Batra #Pfizer #Novartis #MinipressXL #PfizerIndia #NovartisIndia #CNBCTV18Digital - LinkedIn
Precision Trading with Pfizer Inc. (PFE) Risk Zones - Stock Traders Daily
Novartis India acquires Pfizer brands for $132m - Yahoo Finance
Pfizer shares hit 52-week low after Minipress XL discontinuation; Novartis zooms 13% - Business Today
Novartis India to Acquire Minipress, Minipres Trademarks From Pfizer for Rs 1,250 Crore - Medical Dialogues
Pfizer to Discontinue Minipress XL in India, Receives USD 13.9 Mn From US Parent - Medical Dialogues
Pfizer stock heads into the open after a flat close - ad-hoc-news.de
Pfizer (PFE) Hands Broad Rights On CD228V In New Oncology Licensing Deal - simplywall.st
Forget the Dividend. This Could Be the Real Reason to Buy Pfizer Stock Now - Yahoo Finance
Maharashtra: Novartis India buys Minipress brands from Pfizer for Rs 1250 crore - Deccan Chronicle
This Is What I'd Do With Pfizer Stock Right Now - The Globe and Mail
Novartis India to Acquire Pfizer’s Minipress Trademarks for Rs 1,250 Crore - ChemAnalyst
Novartis India Ltd to acquire BP drug trademarks from Pfizer Inc, for ₹1,250 crore - BusinessLine
ChrysCap-controlled Novartis India to buy Pfizer’s blood pressure brand Minipress - VCCircle
Novartis India buys Minipress brands from Pfizer for ₹1,250 crore - Business Standard
Novartis India to acquire Pfizer's 'Minipress' trademark for ₹1,250 crore - ET Manufacturing
Novartis India to Buy Pfizer’s Minipress Brand for Rs 1,250 Cr - Equitypandit
Pfizer Inc. stock gains on Minipress XL exit and solid Q2 2026 figures - ad-hoc-news.de
Novartis India to acquire Minipress, Minipres Trademarks from Pfizer for Rs 1,250 crore - Business Upturn
Novartis India: Why Is the Pharma Stock Spending ₹1,250 Crore to Acquire Pfizer’s Minipress Brand? - Trade Brains
Pfizer, Inc. (PFE) Stock Analysis: Evaluating the 6.05% Dividend Yield and Its Implications for Investors - DirectorsTalk Interviews
Novartis India Expands Portfolio With INR 1,250 Crore Acquisition of Pfizer's Minipress Trademarks - latestly.com
Pfizer to Receive Rs 131.38 Crore After Minipress XL Discontinuation; Know Details - Dalal Street Investment Journal
Novartis India to acquire Pfizer trademarks 'Minipress' and 'Minipres' for Rs 1,250 crore - Mid-Day
Novartis India buys Minipress, Minipres rights from Pfizer for ₹1,250cr - NewsBytes
Novartis India Buys Minipress From Pfizer For ₹1,250 Crore - Whalesbook
Minipress changes hands: Novartis India buys Pfizer brands for Rs 1,250 crore - Moneycontrol.com
Novartis India to acquire Pfizer's 'Minipress' trademark for Rs 1,250 crore - The Economic Times
Novartis India to acquire Pfizer's ‘Minipress’ trademark for ₹1,250 crore - BusinessLine
Pfizer to cease Minipress XL operations, secures USD 13.9 million from US parent - Business Upturn
Novartis India Acquires Pfizer's Minipress for ₹1,250 Cr - Rediff MoneyWiz
Novartis India shares jump 4% on Rs 1,250 crore Pfizer trademarks acquisition - Business Today
Novartis India Buys Minipress Brand For ₹1,250 Crore, Pfizer To Stop Selling Hypertension Drug - Free Press Journal
Pfizer to Discontinue Minipress XL, Receives $13.9M - InvestyWise
Novartis India to acquire Minipress, Pfizer’s high blood pressure drug, for ₹1,250 crore - CNBC TV18
Pfizer Inc Stock (PFE) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.40%
1.97%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):